C-Met in invasive breast cancer: Is there a relationship with the basal-like subtype?

Cancer

Volumn 120, Issue 2, 2014, Pages 163-171

  Ho Yen, Colan M ^a   Green, Andrew R ^b   Rakha, Emad A ^b   Brentnall, Adam R ^a   Ellis, Ian O ^b   Kermorgant, Stephanie ^a   Jones, J L ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

basal like; breast cancer; c Met; triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 84891845042     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28386     Document Type: Article

References (51)

1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874.
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 8418-8423.
4. Perou CM,. Molecular stratification of triple-negative breast cancers. Oncologist. 2011; 16 (suppl 1): 61-70.
5. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109: 123-139.
6. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003; 95: 1482-1485.
7. Ray PS, Wang J, Qu Y, et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 2010; 70: 3870-3876.
8. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14: 1368-1376.
9. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009; 15: 2302-2310.
10. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010; 7: e1000279.
11. Hanna JA, Bordeaux J, Rimm DL, Agarwal S,. The function, proteolytic processing, and histopathology of Met in cancer. Adv Cancer Res. 2009; 103: 1-23.
12. Gastaldi S, Comoglio PM, Trusolino L,. The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res. 2010; 12: 208.
13. Peschard P, Park M,. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene. 2007; 26: 1276-1285.
14. Nakamura T, Sakai K, Nakamura T, Matsumoto K,. Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol. 2011; 26 (suppl 1): 188-202.
15. Lai AZ, Abella JV, Park M,. Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 2009; 19: 542-551.
16. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997; 16: 68-73.
17. Stella GM, Benvenuti S, Gramaglia D, et al. MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat. 2011; 32: 44-50.
18. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 1039-1043.
19. Kim CH, Kim J, Kahng H, Choi EC,. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma. Ann Surg Oncol. 2007; 14: 1565-1574.
20. Li Y, Chen CQ, He YL, et al. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012; 106: 304-310.
21. Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005; 113: 678-682.
22. Jin L, Fuchs A, Schnitt SJ, et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer. 1997; 79: 749-760.
23. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL,. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer. 1998; 82: 1513-1520.
24. Camp RL, Rimm EB, Rimm DL,. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer. 1999; 86: 2259-2265.
25. Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL,. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer. 2003; 97: 1841-1848.
26. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G,. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12: 89-103.
27. National Institutes of Health. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://www.clinicaltrials.gov. Accessed April 20, 2013.
28. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004; 91: 1532-1542.
29. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005; 116: 340-350.
30. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4: 844-847.
31. Hsu SM, Raine L, Fanger H,. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29: 577-580.
32. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR,. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat. 2011; 127: 591-599.
33. Camp RL, Dolled-Filhart M, Rimm DL,. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10: 7252-7259.
34. Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006; 25: 2273-2284.
35. Graveel CR, DeGroot JD, Su Y, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A. 2009; 106: 12909-12914.
36. Garcia S, Dalès JP, Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol. 2007; 38: 830-841.
37. Kuroda H, Ishida F, Nakai M, Ohnisi K, Itoyama S,. Basal cytokeratin expression in relation to biological factors in breast cancer. Hum Pathol. 2008; 39: 1744-1750.
38. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502.
39. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006; 49: 22-34.
40. Manié E, Vincent-Salomon A, Lehmann-Che J, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 2009; 69: 663-671.
41. Lindemann K, Resau J, Nährig J, et al. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 2007; 51: 54-62.
42. Foulkes WD, Grainge MJ, Rakha EA, Green AR, Ellis IO,. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat. 2009; 117: 199-204.
43. Nakopoulou L, Gakiopoulou H, Keramopoulos A, et al. c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology. 2000; 36: 313-325.
44. Carracedo A, Egervari K, Salido M, et al. FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. Breast Cancer Res. 2009; 11: 402.
45. Chen HH, Su WC, Lin PW, Guo HR, Lee WY,. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res Treat. 2007; 103: 167-175.
46. Reshetnikova G, Troyanovsky S, Rimm DL,. Definition of a direct extracellular interaction between Met and E-cadherin. Cell Biol Int. 2007; 31: 366-373.
47. Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C,. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008; 68: 1471-1477.
48. Mueller KL, Hunter LA, Ethier SP, Boerner JL,. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 2008; 68: 3314-3322.
49. Minuti G, Cappuzzo F, Duchnowska R, et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer. 2012; 107: 793-799.
50. Kang JY, Dolled-Filhart M, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 2003; 63: 1101-1105.
51. Zagouri F, Bago-Horvath Z, Rössler F, et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer. 2013; 108: 1100-1105.